Börse München (Südseiten): Strengthening Germany as a Financing Location

"Why do vaccine manufacturers like BioNTech SE or CureVac go public in the USA, even though they were co-financed here in Germany with German taxpayers' money?" asks Dr Norbert Kuhn in his article. The conclusion: more capital via pension schemes and more flexibility in stock corporation law - these are the levers that the next federal government must pull to ensure that ideas can also be financed in Germany. If this succeeds, innovative business models will not migrate abroad, jobs will be secured and growth and prosperity in Germany will increase.

The article by Dr Norbert Kuhn appeared in the Südseiten of the Börse München.